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Abstract 
The joint 5th Pan Arab Human Genetics conference and 2013 Golden Helix 
Symposium, “Genomics into Healthcare” was co-organized by the Center for Arab 
Genomic Studies (CAGS - http://www.cags.org.ae) in collaboration with the Golden Helix 
Foundation (http://www.goldenhelix.org) in Dubai, United Arab Emirates from 17-19 
November, 2013. The meeting was attended by over 900 participants, doctors and 
biomedical students from over 50 countries and was organized into a series of nine 
themed sessions that covered cancer genomics and epigenetics, genomic and 
epigenetic studies, genomics of blood and metabolic disorders, cytogenetic diagnosis 
and molecular profiling, next generation sequencing, consanguinity and hereditary 
diseases, clinical genomics, clinical applications of pharmacogenomics and genomics in 
public health. 
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Introduction 
The joint 5th Pan Arab Human Genetics conference and 2013 Golden Helix 
Symposium, “Genomics into Healthcare”, hosted by Sheikh Hamdan Bin Rashid Al 
Maktoum Award for Medical Sciences and organized by the Center for Arab Genomic 
Studies (CAGS - http://www.cags.org.ae) in collaboration with the Golden Helix 
Foundation (http://www.goldenhelix.org) was held from 17-19 November, 2013 in Dubai, 
UAE. The 3-day conference was opened by His Excellency Prof. Najib Al Khaja, 
Secretary General of Sheikh Hamdan Bin-Rashid Al Maktoum Award for Medical 
Sciences (http://www.hmaward.org.ae) and President of CAGS. 
The meeting was attended by over 900 participants, doctors and biomedical 
students from over 50 countries and featured 50 lectures and over 100 poster 
presentations. Sponsored by the Gulf Scientific Corporation, the meeting was organized 
into a series of nine themed sessions that covered: 1) cancer genomics and epigenetics; 
2) genomic and epigenetic studies; 3) genomics of blood and metabolic disorders; 4) 
cytogenetic diagnosis and molecular profiling; 5) next generation sequencing; 6) 
consanguinity and hereditary diseases; 7) clinical genomics; 8) clinical applications of 
pharmacogenomics; and, 9) genomics in public health. 
 
Opening Keynote 
The opening Keynote lecture was given by Prof. David N. Cooper (Cardiff, UK) 
on the molecular basis of reduced (or incomplete) penetrance in inherited human 
disease. He discussed how reduced penetrance can be a function of factors such as 
specific mutation(s), allele dosage, differential allelic expression, copy number variation 
and the influence of additional genetic variants (in cis or in trans).  
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Studies of Arab populations 
The Arab world comprises 22 countries and extends from Mauritania in the west 
to Oman in the east (Figure 1). Across this vast region also known as MENA (Middle-
East and North Africa), genetic disorders are relatively common and account for a 
substantial proportion of physical and mental handicaps. Large family size, older 
parental age, high consanguinity rate (40-68%), first cousin marriages and the 
considerable presence of tribal groups contribute to the burden of genetic diseases in 
these societies. However, despite experiencing numerous cultural, legal and religious 
challenges, several Arab countries have active prevention programs for some common 
genetic disorders including hemoglobinopathies and Down syndrome.  
Towards the goal of collecting omics data, several large-scale genetics initiatives 
relating to the Arab world were featured at the meeting. Dr. Abdul Rezzak Hamzeh 
(UAE) described the work of CAGS. Founded in 2003, it hosts the “Catalogue for 
Transmission Genetics in Arabs” (CTGA), an open-access database 
(http://cags.org.ae/ctga_search.html) that contains over 1,600 disease and gene records 
and is the major global resource for genetic information in Arabs. Other initiatives include 
the Genome Arabia Project that plans to sequence up to 500 individuals from seven 
countries in the region including Qatar, Bahrain, Kuwait, United Arab Emirates, Tunisia, 
Lebanon and Saudi Arabia using next-generation sequencing (NGS) technologies in 
order to identify disease-causing mutations (http://www.bbc.co.uk/news/health-
25216135). 
The Weill-Cornell Medical College in Qatar has conducted a number of next-
generation medical genomics projects, including family and cohort studies of diabetes, 
obesity, inherited neuropathies and cancer. The data generated has been deposited in 
the Qatar Genome Browser (QGB), a web-based data portal, which provides an 
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interface to the public for study focused on NGS-omics data. QGB is the first of its kind 
in the MENA region. 
Dr. Arif Anwar from Sengenics (Malaysia; http://www.sengenics.com), the first 
Asia-based genomics research and molecular diagnostics company, presented a novel 
pipeline for identification of clinically significant mutations using array-comparative 
genomic hybridization (a-CGH) combined with whole exome sequencing (WES). This 
large-scale study of pediatric disorders in the Arab population screened approximately 
1,000 samples for variants in 20,000 genes. Identification of clinically significant 
mutations using combined aCGH/WES resulted in a significant increase in diagnostic 
yield.  
Dr. Ilham Ratbi gave an outline of the Moroccan National/Ethnic Mutation 
Database (NEMDB; http://www.sante.gov.ma/departements/inh/mohumuda/) was 
initiated in 2007. It aims to provide researchers and clinicians with up-to-date information 
about genetic variants in various genes known to cause genetic disorders that have 
been detected in Moroccan patients. To date, the database contains 425 mutations and 
208 polymorphisms found in 301 genes and 259 diseases. Autosomal recessive mode of 
inheritance accounts for 74.17% of the genetic disease burden in the Moroccan 
population. This database has recently been migrated to the new ETHNOS platform and 
upgraded with new data and novel data querying and visualization tools (Papadopoulos 
et al., 2014). The migration of the Moroccan NEMDB to the new ETHNOS platform is 
part of a broader project involving development of new and migration of existing 
NEMDBs to the upgraded ETHNOS platform that is encouraged by the Genome 
Informatics Working Group of the Genomic Medicine Alliance 
(www.genomicmedicinealliance.org). 
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Dr. Mohammed Naveed presented the results of his study in identifying the 
genetic modifiers of a rare and severe limb deformity in a large Emirati family.  Dr. Erol 
Baysal from the Dubai Health Authority shed light on the use of chorionic villus sampling 
and the latest in DNA-based diagnostics and how the accurate detection and counseling 
of at-risk couples is helping to reduce the mortality and morbidity from beta-thalassemia. 
Prof. Aida Al Aqeel explored the challenges as well as the progress and recent 
advances in the implementation of personalized transitional genomics in the clinical 
setting. She stressed that in Saudi Arabia, pre-implantation genetic diagnosis and 
neonatal screening for genetic metabolic disorders are, at present, the most important 
preventive programmes, and that the country is considering new therapeutic strategies, 
such as personalized therapeutic strategies at the genomics level. 
Additional omics-based initiatives were presented during the conference 
including the European Cytogeneticists Association Register of Unbalanced 
Chromosome Aberrations (ECARUCA; www.ecaruca.net), which collects and provides 
cytogenetic and clinical information on rare chromosomal disorders, including 
microdeletions and microduplications. ECARUCA is a multi-lingual database that 
contains over 2,500 types of aberrations. In the same vein, the conference included a 
workshop about Rd-CONNECT (http://rd-connect.eu), which is a unique global 
infrastructure project that links up databases, registries, biobanks and clinical 
bioinformatics data used in research on rare diseases to act as a central resource for 
researchers worldwide. Together with other two multicenter projects, namely Neuromics 
(www.rd-neuromics.eu) and EURenOmics (www.rd-eurenomics.eu) coordinated by Prof. 
Olaf Riess and Franz Schaefer, respectively, RD-CONNECT  allows scientists to share 
data from their genomics research projects leading to faster diagnosis, better treatments 
and quality of life improvement for patients with rare diseases. 
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Special medical issues in the Arab world 
The conference highlighted some of the special medical issues in the Arab world 
such as increased homozygosity due to consanguinity, which is linked to a high overall 
risk of cancer. Dr. Lotfi Chouchane (Qatar) reported that breast cancer is the most 
common malignant disease in women from Arab populations comprising up to 42% of all 
tumors, and presenting 10 years earlier than in women from Western Europe 
(Chouchane et al, 2013). It was also shown that triple negative breast cancer (i.e., any 
breast cancer that does not express the genes for estrogen receptor, progesterone 
receptor and Her2/neu) is more common in this part of the world. This data contrasts 
with the incidence of breast cancer in Europe and the USA, where the incidence has 
fallen in recent years. 
Recessive disorders are highly prevalent in the UAE due to high rates of 
consanguinity among many of its subpopulations. However, the molecular causes 
underlying many of the rare recessive disorders are still unknown. Advances in NGS and 
bioinformatics have significantly expedited the discovery of the defective genes and 
mutations of many genetic conditions. Dr. Nadia Akawi (UAE) presented the UAE 
experience on the usage of WES for the identification of genes and mutations of several 
rare recessive disorders including those causing intellectual disability, macrocephaly, 
multiple dysplasia and distinctive facial appearance. Diagnoses were also obtained in 
heterogeneous cases of congenital muscular dystrophy with brain and eye anomalies, 
for camptodactyly-arthropathy-coxa vara-pericarditis syndrome (Akawi et al, 2012). 
A poster by Amal Al hashem and colleagues presented a study of 19,165 births 
in a Saudi population that showed that consanguinity is an independent risk factor for the 
high rate of birth defects in a population with a high rate of consanguineous marriages 
(Saadallah and Rashed, 2007). Consanguinity has a statistically significant contribution 
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in cases of genetic syndromes, and isolated renal defect. However, consanguinity has 
no statistically significant contribution in cases of chromosomal aberrations, isolated 
congenital heart disease and multiple malformations. 
The role of inbreeding and the risk of developing type 2 diabetes (T2D) was 
presented through a poster by Dr. Ibrahim Gosadi (Saudi Arabia) suggesting that 
consanguinity might increase risk of T2D by earlier development of the disease, and by 
strengthening possible genetic effects on fasting blood glucose. 
A poster by Dr. Tim Yu and colleagues showed the contribution of consanguinity 
in autism spectrum disorders (ASDs) in a study of over 200 families. Multiple 
approaches, including linkage analysis, homozygosity mapping and WES, show that 
consanguineous families with autistic children have a significantly different genetic 
architecture than non-consanguineous families, with fewer de novo events and an 
enrichment of recessive point mutations and deletions. Recessive cases also 
demonstrate that ASD can be an unexpected manifestation of partial loss-of-function 
mutations in genes with more classical syndromic associations, and illustrate how further 
study of consanguineous ASD families will be important in dissecting this complex and 
heterogeneous disorder. 
Prof. Hanan Hamamy provided a highly instructive talk on the feasibility of 
applying new technologies to help consanguineous couples at risk of having affected 
children. These techniques could help in the detection of shared known autosomal 
recessive pathogenic variants giving the opportunity for these couples to decide on their 
reproductive options.   
Furthermore, a significant number of the presentations and posters addressed 
specific problems in Arab countries including: birth defects and genetic conditions in 
Oman (Prof. Anna Rajab); breast cancer and hearing loss in Palestine (Dr. Moien Nihad 
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Kanaan); pharmacogenetics of warfarin metabolism, oral-facial-digital type 1 syndrome 
and geleophysic dysplasia in UAE (Dr. Hayat Aljebeji); intellectual and developmental 
disabilities in Lebanon (Prof. Andre Megarbane); autosomal recessive disorders, 
myeloproliferative neoplasms, and copy number variants in Qatar (Dr. Tawfeg Ben-
Omran and Dr. Khalid Fakhro); nasopharyngeal carcinoma, psoriasis and breast cancer 
risk in Tunisians (Dr. Wijden Mahfoudh); mutated ANKRD26 gene and familial 
thrombocytopenia. in Saudi Arabia (Dr. Walid Dridi); hypertriglyceridemia and risk of 
coronary artery disease (CAD) in arterial hypertensive Moroccan patients (Dr. Sanaa 
Ouatou); genetic polymorphisms and cardiovascular risk factors of Alzheimer disease in 
Algerian population (Dr. Ouldjaoui Ahmed); and novel mutations in the NLRP7 gene in 
two Egyptian families (Dr. Ebtesam Abdalla). 
 
Pharmacogenomics 
Pharmacogenomics holds promise to rationalize drug use by increasing drug 
efficacy and minimizing drug toxicity. In developing countries, pharmacogenomics can 
also contribute towards reducing healthcare expenditure at a national level. Prof. George 
Patrinos (Greece) presented preliminary data indicating that there are significant 
differences among various European populations regarding pharmacogenomic 
biomarkers allele frequencies that can be readily applicable to rationalize drug use in 
these countries (Mette et al., 2012). Also, he presented data from whole genome 
sequence analysis of 482 unrelated individuals of various ethnic backgrounds to obtain 
their personalized pharmacogenomic profiles, indicating that a significant number of 
novel pharmacogenomically relevant variants can be identified using this approach 
(Mizzi et al, submitted). Also, these findings were replicated in a 7-member family of 
Greek origin in an effort to explain the variable response rate to acenocoumarol 
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treatment in two family members. Overall, these data demonstrate that whole genome 
sequencing is necessary to accurately determine an individual’s pharmacogenomics 
profile. 
Additional clinical applications of pharmacogenomics were illustrated by Prof. 
Ron van Schaik, who described the work at his laboratory. They have offered PGx 
testing in close collaboration with the hospital pharmacy since 2005 and have tested 
over 2,000 patients. The fifteen different markers, most commonly ordered involve the 
TPMT and CYP2D6 genes, including the HLA-A*3101 with a growth rate of 40-50% tests 
requests per year (Elens et al, 2013). In this context, an important PGx resource is 
Pharmacogenomics Knowledge Base (PharmGKB, www.pharmgkb.org), a publicly 
available Internet research tool developed by Stanford University that encompasses 
clinical information including dosing guidelines and drug labels, potentially clinically 
actionable gene-drug associations, and genotype-phenotype relationships. PharmGKB 
collects curates and disseminates knowledge about the impact of human genetic 
variation on drug responses.  
 
Large-scale sequencing projects 
Another theme running through the conference was how to implement large-
scale sequencing projects on very large groups. The largest of these initiatives is “The 
Million Human Genomes Project” launched in November 2011 by Beijing Genomics 
Institute (BGI; http://www.genomics.cn) to decode the genome of over 1 million people. 
Features of this project, illustrated by Prof. Jun Wang (BGI, Beijing, China), comprise 
five essential parts: 1) Ancient genomes; 2) Population genomes; 3) Medical genomes; 
4) Cell genomes; and, 5) Personal genomes. The aim of this project is to establish a 
research baseline and reference standard for specific populations, as well as to connect 
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the phenotypes of diseases and traits with the genetic variations in order to understand 
the disease mechanism. The integrative genome message and scientific discoveries 
obtaining from the project will lay the foundation for guiding innovative clinical diagnosis 
and treatment, and ultimately advancing personalized healthcare and improving human 
health (http://www.genomics.cn/en/navigation/show_navigation?nid=5658). The 
technology employed for this endeavor was shown by Dr. Radoje Drmanac, who 
illustrated the benefit and advantages of nanoarrays for sequencing at several tera-
bases per day per instrument (Drmanac et al, 2010). 
 
Genomics into Healthcare 
The conference highlighted a number of issues at the interface of genomics and 
healthcare and the importance of NGS. Prof. Hilger Ropers (Germany) discussed 
intellectual disability (ID) and presented a novel diagnostic tool that utilizes WES and a 
proprietary algorithm to detect mutations in most of the presently known ID genes. This 
work is based on a previously described test for ~600 severe recessive childhood 
disorders (Bell et al, 2010) and on a comprehensive list of genes implicated in ID. 
Furthermore, he anticipated that the technology will shed light on the molecular causes 
of ID and related conditions such as autism, schizophrenia and epilepsy, which are still 
largely unknown. 
Prof. Maurizio Ferrari (Italy) showed his work with 91 patients that resulted in the 
identification of novel variants which could be critical for improving risk stratification and 
clinical management of asymptomatic patients with Brugada syndrome. The 
predisposition for these patients to develop fatal arrhythmias cannot be easily predicted 
and no anti-arrhythmic drug is effective in preventing these life-threatening arrhythmias. 
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Prof. Ahmad Al Marzouqi’s lecture introduced three new chromatin remodelers 
that have been identified by his team: Fun30, Irc5 and Irc20. All three complexes share 
some common features, including the presence of a distinct ATPase domain. 
How the transcriptional and epigenetic programs interact on the chromatin 
encompassing the human alpha globin cluster and its regulatory elements on 
chromosome 16 was shown by Prof. Douglas Higgs. The interaction was uncovered, 
using a variety of approaches to show how genes within their natural chromosomal 
environment are switched on and off during hematopoiesis. These findings add to our 
general understanding of the relationship between genome structure and function.  
The aldehyde dehydrogenase (ALDH) superfamily (19 genes in the human 
genome) is of increasing interest. Prof. Vasilis Vasilou (USA) presented work on the 
recent discovery of ALDHs as markers of cancer stem cells and their involvement in 
cancer cell resistance to chemotherapy and radiotherapy. As a result, it is anticipated 
that ALDH may be a therapeutic target in cancer in the near future. 
Prof. Achilleas Gravanis (Greece) described his work on the neuroprotective 
actions of microneurotrophins in various animal models of neurodegenerative diseases 
as well as in fetal and adult neural stem cells. Microneurotrophins may serve as lead 
molecules to develop neurotrophin-like small molecules that can cross the blood-brain 
barrier with potential applications in the treatment of neurodegenerative diseases. 
 
Closing Keynote 
The meeting closed with a keynote speech by Prof. Angela Brand (The 
Netherlands) on “Genomics in Public Health”. She stressed the need to change our 
perspective from diseases to diseasomes, risk factor to risk pattern, clinical utility to 
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personal utility, and from complex disorders to multiple rare diseases (Brand, 2012). This 
is in line with P4 Medicine (predictive, personalized, preemptive and participatory) and 
the anticipated era of precision medicine (Hood and Flores, 2012). Dr. Brand described 
public health genomics (PHG), the area of public health ensuring that scientific advances 
in genomics are effectively and responsibly translated into health policies and practices 
for the benefit of population health, and the connected activities needed for its 
implementation (Brand, 2012). Her Institute aims to fulfill this task for European Member 
States via the European Centre for Public Health Genomics (ECPHG). 
 
Conclusions  
 The joint 5th Pan Arab Human Genetics conference and 2013 Golden Helix 
Symposium offered a highly valuable opportunity for Arab scientists to join forces with 
international geneticists in order to accelerate the advancement of human genetics 
worldwide. The importance of this event stemmed from bringing together 
multidisciplinary expertise with the goal of improving medical care. In fact the worldwide 
divide between “blue sky” research and clinical practice is a huge barrier to applying 
recent advances in genomics into the practice of medicine. This divide was directly 
targeted by this conference, which met its objectives of attracting top-level research and 
making scientists and medical professionals think of their work in a new way so as to 
serve the ultimate goal: a healthier society through cutting-edge scientific discoveries.  
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 Figure Legends 
Figure 1.   
Map of the Arab World (Algeria, Bahrain, Comoros, Djibouti, Egypt, Iraq, Jordan, Kuwait, 
Lebanon, Libya, Mauritania, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Somalia, 
Sudan, Syria, Tunisia, United Arab Emirates, Yemen 
territory). Comoros is not shown)
(http://en.wikipedia.org/wiki/File:Arab_World_Green.png#filelinks
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(Western Sahara is a disputed 
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